This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough

Company Overview - Xenon Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel therapeutics for neurological conditions, particularly epilepsy [5][6] - The company has a robust pipeline of potassium and sodium channel modulators, with key drug candidates including XEN496, XEN1101, NBI-921352, and XEN007 [6][7] - As of the latest data, Xenon has a market capitalization of $4.9 billion and reported revenue of $7.50 million, with a net income of -$345.91 million [4] Recent Developments - On February 17, 2026, Driehaus Capital Management disclosed an increase in its position in Xenon Pharmaceuticals by 369,577 shares, valued at approximately $15.52 million [1][2] - The total value of Driehaus's position in Xenon rose by $36.03 million due to both the increased stake and market price changes [2] - Following strong Phase 3 trial results for its lead drug candidate, azetukalner, which showed a median seizure reduction of 53.2% in treated patients, Xenon plans to file for U.S. regulatory approval later this year [8][9] Market Performance - Xenon shares were priced at $58.33, reflecting a 66% increase over the past year, significantly outperforming the S&P 500's 19% gain during the same period [5][9] - The company's recent public offering of $747.5 million has strengthened its balance sheet, aiding in commercialization efforts and pipeline expansion [9] Investment Positioning - Driehaus Capital Management's stake in Xenon now represents 1.4% of its 13F reportable assets under management, positioning it alongside other neuroscience-focused investments [5][10] - The recent momentum in Xenon's stock performance suggests it may stand out among its peers in the biotechnology sector [10]